Baldwin IP PLLC is proud to announce that Best Lawyers® has recognized founder Alison Baldwin in the 2027 edition of The Best Lawyers in America®, in the following areas: Litigation - Intellectual Property Litigation - Patent Patent Law. Alison has been a recipient of Best Lawyers recognition since 2020 in Patent Law and since 2021 in Litigation - Intellectual Property. Best Lawyers awards recognition through a purely peer-review process. Lawyers cannot pay for inclusion; eva

Watch the replay of our July webinar on patents, trade secrets, and trademarks for startups, plus a due diligence checklist investors and acquirers actually use.

On July 28, Alison Baldwin and Michael Wiwchar of Baldwin IP PLLC are hosting a free, 60-minute webinar to help founders and innovators build a complete IP strategy, from the first idea through Series A and beyond. What We Will Cover An effective IP strategy involves a sequence of decisions made over time, each shaped by where your company stands, how much runway you have, and what competitors are doing in your space. The layers of IP protection. Patents, trade secrets, trade

Every year your product spends in regulatory review is a year of patent value consumed before you reach market. The Farm Bill just created the first dedicated biotechnology policy office inside USDA. Most coverage missed the two years of federal coordination work that came before it — and why that history is the part that matters for your patent strategy.

The FAO's 2026 theme is 'Plant biosecurity for food security and nutrition.' Behind that phrase is a straightforward argument: the innovations protecting crops from disease and pests depend on intellectual property protection to exist. Here's what that means in practice.

In a month, I'll be heading to San Francisco for two premier conferences that bring together some of the brightest minds in agricultural and food technology innovation. World Agri-Tech Innovation Conference | March 17-18Future Food-Tech Conference | March 19-20 San Francisco Marriott Marquis I'm looking forward to connecting with founders, researchers, and investors working on: 🌾 Gene editing and precision breeding 🤖 AI applications in agriculture 🔬 Precision fermentation

The decision by the Supreme Court of the United States to review Amarin v. Hikma places renewed focus on a recurring challenge in patent law: how to balance the economies of generic competition with the need for meaningful incentives for innovation. While the case comes out of the pharmaceutical industry, its implications could also directly extend into the agrichemical industry and may also extend into other regulated technology sectors where method-based patents and governm

For years, ex parte reexamination has lived in the shadow of post-grant review. But as PTAB practice evolves and litigation strategies adapt, its utility is becoming harder to ignore. In the right case, it can function not as a blunt instrument, but as a precision tool—quietly reshaping risk, leverage, and outcomes in parallel litigation.

The AgTech patent boom is not a passing trend. As agriculture becomes more data-driven, automated, and sustainability-focused, universities will remain primary sources of early-stage innovation. Technology transfer offices that understand how AgTech companies assess risk, value, and deployment will be best positioned to translate their innovation into real-world impact.

The lawsuits filed by Bayer CropScience against Moderna, Pfizer, and Johnson. Although the cases are in early stages and all players will have to see how they play out, ultimately, the very fact that these cases exist serves as a cautionary tale and a roadmap. Innovators in both the pharmaceutical and agribusiness spaces should anticipate cross-industry IP risks, invest in early licensing strategies, and draft patents with an eye toward future, unforeseen applications.

Just one month left until the AUTM 2026 Annual Meeting in Seattle, and I’m looking forward to connecting with colleagues and friends in the tech transfer space. If you’re attending too—whether you’re from a university tech transfer office, a startup, or somewhere in between—I’d love to say hello, grab a coffee, or compare notes on what you’re seeing in IP, licensing, and life sciences innovation. If you’ll be in Seattle, feel free to reach out. Hope to see you there. - Alison